|Home | About | Journals | Submit | Contact Us | Français|
Mood disorders are associated with regional brain abnormalities, including reductions in glial cell and neuron number, glutamatergic irregularities, and differential patterns of brain activation. Because astrocytes are modulators of neuronal activity and are important in trafficking the excitatory neurotransmitter glutamate, it is possible that these pathologies are interrelated and contribute to some of the behavioral signs that characterize depression and related disorders. We tested this hypothesis by determining whether depressive-like signs were induced by blocking central astrocytic glutamate uptake with the astrocytic glutamate transporter (GLT-1) inhibitor, dihydrokainic acid (DHK), in behavioral tests that quantify aspects of mood, including reward and euthymia/dysthymia: intracranial self-stimulation (ICSS) and place conditioning. We found that DHK elevated ICSS thresholds, a depressive-like effect that could reflect reduced sensitivity to reward (anhedonia) or increased aversion (dysphoria). However, DHK treatment did not establish conditioned place aversions, suggesting that this treatment does not induce dysphoria. To identify the brain regions mediating the behavioral effects of DHK, we examined c-Fos expression in areas implicated in motivation and emotion. DHK increased c-Fos expression in many of these regions. The dentate gyrus of the hippocampus was robustly activated, which led us to explore whether DHK alters hippocampal learning. DHK impaired spatial memory in the MWM. These findings identify disruption of astrocyte glutamate uptake as one component of the complex circuits that mediate anhedonia and cognitive impairment, both of which are common symptoms of depression. These finding may have implications for the etiology of depression and other disorders that share the features of anhedonia and cognitive impairment.
Little progress has been made over the past 20 years in identifying more effective treatments for Major Depressive Disorder (MDD). This may be due, in part, to a lack of knowledge about specific abnormalities present in the depressed brain. Because all currently available antidepressants were discovered serendipitously, the mechanisms of action for effective antidepressant treatment remains largely unknown (Nestler and Carlezon, 2006). This work is designed to help identify the cellular or molecular mediators of behavior that could be novel treatment targets by mimicking behavioral abnormalities reported in depressed humans and evaluating the potential role of these mediators in the etiology of depressive illness.
MDD is associated with distributed regional abnormalities of the brain, including fewer glial cells (Bowley et al, 2002; Cotter et al, 2002; Cotter et al, 2001; Hamidi et al, 2004; Hercher et al, 2009; Müller et al, 2001; Öngür et al, 1998; Rajkowska, 2000; Rajkowska et al, 1999), fewer neurons (Arango et al, 1996; Baumann et al, 2002; Law and Harrison, 2003; Rajkowska et al, 1999), alterations in glutamate function (Paul and Skolnick, 2003; Pittenger et al, 2007; Sanacora et al, 2008; Valentine and Sanacora, 2009), and anomalous patterns of regional brain activation (Milak et al, 2005; Videbech, 2000; Wu et al, 2001). Over- or under-activation in specific brain regions can be associated with specific symptoms of depression, although an overall positive association is observed between severity of depression and activation of a distributed cortico-limbic circuit (Milak et al, 2005). Furthermore, normalization of activity is associated with alleviation of depressive symptoms (Buchsbaum et al, 1997; Kennedy et al, 2001; Mayberg et al, 1997; Mayberg et al, 2000; Mayberg et al, 2005; Pizzagalli et al, 2001; Wu et al, 1999). The role of each of these pathologies in the etiology of mood disorders is unknown. However, because astrocytes are crucial for the uptake of the excitatory neurotransmitter glutamate (Anderson and Swanson, 2000; Danbolt, 2001), it is possible that some of these pathologies are causally interrelated. Recent reports point to a causal link between glutamate and the treatment of depression by showing that ketamine, an antagonist of glutamatergic NMDA receptors, has antidepressant-like effects in humans and laboratory animals (Berman et al, 2000; Maeng et al, 2007; Zarate et al, 2006). Preclinical studies suggest that cortical glial ablation (Banasr and Duman, 2008) and blockade of astrocytic glutamate uptake in the amygdala (Lee et al, 2007) or ventral tegmental area (Herberg and Rose, 1990) can produce some depressive-like effects and that levels of the astrocytic glutamate transporter (GLT-1 aka EAAT2; Anderson and Swanson, 2000; Danbolt, 2001) are decreased in an animal model of depression (Zink et al, 2010). Thus, there is accumulating evidence that glutamate neurotransmission and glial cells could be involved in both the causes and the treatment of depression. Because glial cell reduction has been reported in several limbic regions and increased limbic activation is positively associated with symptom severity, we examined the effects of central blockade of astrocytic glutamate uptake using the GLT-1 inhibitor dihydrokainic acid (DHK; Anderson and Swanson, 2000 Arriza et al, 1994) in rats using tests that can quantify various symptoms of depression.
Features of the depressive syndrome that can be modeled in rats include states of anhedonia (diminished sensitivity to reward) and dysphoria (discomfort, observable as aversion). Intracranial self-stimulation (ICSS) is a paradigm that detects both diminished and enhanced reward states (Carlezon and Chartoff, 2007). Although ICSS is a powerful tool for quantifying motivation, it is difficult to distinguish anhedonia-like behavior from dysphoria-like behavior in this paradigm as both produce the same outcome: treatments that block reward (eg, dopamine antagonists) and induce aversion (eg, acute opiate withdrawal) elevate reward thresholds (Carlezon and Chartoff, 2007). Place conditioning has been widely used to study the rewarding and aversive properties of drugs (for review see Carlezon, 2003; Tzschentke, 2007). We used the effects in this paradigm to interpret the effects in the ICSS paradigm because tests of place conditioning can detect dysphoria (increased aversion) separately from anhedonia (decreased reward). Finally, we used c-Fos immunoreactivity to begin to identify brain areas that may mediate the observed effects. We hypothesized that intracranial DHK infusions would produce a depressive-like phenotype and that DHK would selectively alter the activity of a forebrain circuit related to the processing of emotional stimuli.
Seventy-three male Sprague–Dawley rats (Charles River Laboratories Inc.) weighing 275–300g on arrival were used in these studies. After surgery the rats were housed singly. The rats were maintained on a 12-h light–dark cycle, with food and water available freely. All experiments used separate cohorts of rats, except the activity studies, as detailed below, and were conducted between 1200 and 1800 hours. The procedures were conducted with the approval of the McLean Hospital Institutional Animal Care and Use Committee within the guidelines of The National Research Council's Guide for the Care and Use of Laboratory Animals.
DHK (Tocris Bioscience, Ellisville, MO) blocks the uptake of glutamate into astrocytes (Anderson and Swanson, 2000; Arriza et al, 1994), which leads to increased extrasynaptic glutamate. This effect has been shown ex vivo with synaptosomes (Robinson et al, 1991) and in vivo with microdialysis (Fallgren and Paulsen, 1996). DHK has little or no effect at AMPA/kainate receptors where it is 500 times less potent than kainic acid and 250 times less potent than quisqualic acid (Johnston et al, 1979). Doses were derived from preliminary findings and previously published behavioral data (Lee et al, 2007). DHK was dissolved in PBS (pH 7.4) as previously reported (Lee et al, 2007).
Rats were implanted with monopolar stainless steel stimulating electrodes (0.25mm diameter) aimed at the medial forebrain bundle (10 degree angle; from the bregma 3.0mm anterior±1.6mm lateral, 7.6mm ventral from the dura) and/or intracerebroventricular (ICV) cannulae (23ga.) aimed at the lateral ventricle (from the bregma 0.6mm posterior, 1.4mm lateral, 2.4mm ventral from the dura with additional 1.5-mm injector projection) (Paxinos and Watson, 2004). The rats were anesthetized with Nembutal (65mg/kg, IP). Small burr holes were made in the skull through which an electrode or guide cannula was lowered to the specified depth under stereotaxic guidance. The electrodes and guide cannulae were fastened to the skull using stainless steel screws and dental acrylic. The rats were allowed 5–7 days of recovery.
Intracranial self-stimulation (ICSS) was conducted to assess changes in hedonic state after DHK treatment. The rats were trained on a fixed-ratio-1 (FR1) schedule of reinforcement to obtain brain stimulation as previously described (Tomasiewicz et al, 2008). Sessions began with the delivery of a 5.0-s non-contingent stimulation train of square-wave cathodal pulses (0.1ms pulse duration, 141Hz). Each subsequent lever press resulted in the delivery of a 0.5-s pulse train and illumination of the house light for 0.5s. The stimulation current (100–300μA) was adjusted for each animal to the lowest value that sustained responding at a rate greater than 1 lever press per second. After stable responding was obtained, the rats were trained to lever press for a series of 15 descending frequencies. At the end of each trial, a 5-s time-out period was imposed. The frequency for each successive trial was decreased by 10% (0.05 log10 units). The completion of all 15 descending frequency trials, termed a ‘pass', was achieved in 15min. Four consecutive passes made-up the daily training sessions. The training period typically spanned 6–8 weeks. To characterize the relationship between response strength and reward magnitude, a least-squares best fit line was plotted across the frequencies that maintained responding at 20, 30, 40, 50, and 60% of the maximum response. From this function, the ICSS threshold was defined as the frequency at which the function intersects with the x-axis (theta-0; T0) (Miliaressis et al, 1986), which represents the point at which the stimulation becomes rewarding. The maximum rate of responding (Max Rate) was calculated in parallel to detect impairments in performance. Mean daily ICSS thresholds were determined by averaging the thresholds for the last three passes. Drug test sessions began the day after mean ICSS thresholds varied by <±10% across five training sessions. On the test days rats were allowed to press through three baseline passes, infused ICV with one of four doses (0.0, 12.5, 25.0, 50.0nmol in 1μl) of DHK Anderson and Swanson, 2000; Arriza et al, 1994), and then subjected to three additional passes. Each animal was administered each dose in increasing order on separate test days, with treatment days interspersed with baseline recovery days.
Place conditioning was assessed to determine whether DHK induced an aversive (dysphoric) state. The unbiased apparatus had three chambers consisting of a neutral middle (12L × 21W × 21H cm) chamber and two conditioning chambers that differed in floor texture, wall coloring, and lighting (24L × 18W × 33H cm; Med Associates, St Albans, VT). The experiment proceeded in three phases: habituation/pre-testing, conditioning, and preference testing. On the first day, rats were given an ICV vehicle infusion before being placed in the conditioning apparatus for 30min. This day allowed the rats to habituate to the experimental apparatus and the infusion procedures, and provided a reference point for individual rat bias. For conditioning, the rats were infused with vehicle (CS− trials) or DHK (CS+ trials) on alternating days immediately before being confined to one of the two conditioning chambers for 30min. Treatment and chamber pairing were counterbalanced within groups. Because aversive conditioning is often acquired rapidly, a 30-min preference test was conducted after two conditioning trials (2 CS+, 2 CS−), followed by two additional conditioning trials and a final test. The rats were infused with vehicle before each test and then allowed to explore the apparatus. The time spent in each compartment was monitored using an automated system. The conditioning trial duration (30min) and the DHK doses (0.0, 25.0, 50.0nmol in 1μl) were chosen on the basis of the effects observed in the ICSS study (ie, peak effects within 15min at 25.0 and 50.0nmol DHK).
Because decreases in activity can influence responding in the ICSS paradigm, activity was assessed to determine whether DHK induced motor impairment. Two separate experiments were conducted with lights off or on (15–35lux depending on position), because it was not clear which would be more comparable to lighting in the ICSS paradigm where the chambers are dark when rats are not responding and illuminated by the house light (45lux) for 0.5s after each lever press. The rats were tested 1 week after completion of place conditioning, for lights-off or MWM for lights-on activity testing. The rats were infused with DHK (0.0, 25.0, 50.0nmol in 1μl) immediately before being placed in the activity chamber for 30min. Activity was monitored in automated chambers (43L × 43W × 31H cm; MED Associates, St Albans, VT). Photobeam breaks during 5-min intervals were used to automatically calculate the distance traveled (cm) during each interval.
Immunohistochemistry for c-Fos was conducted to identify the brain regions involved in the effects of DHK. The methods used were as previously described, with the exception of the primary antibody (Bechtholt et al, 2008). Briefly, rats were perfused (4% paraformaldehyde) and brains were post-fixed overnight and then immersed in sucrose solution until saturated. Non-serial 30μm coronal sections were collected and incubated in rabbit anti c-Fos antisera (1:9000; Calbiochem–EMD Bioscience, Darmstadt, Germany) for 24h at 4°C. The sections were then incubated in biotinylated donkey anti-rabbit antiserum (1:200; Jackson Labs, West Grove, PA) for 90min, followed by treatment with the avidin–biotin complex (1:600; ABC Elite Kit, Vector Labs, Burlingame, CA) for 90min at room temperature. The sections were immersed in 0.02% 3,3′-diaminobenzidine-4HCl (DAB; Sigma-Aldrich Co., St Louis, MO) containing 0.01% H2O2 in phosphate buffer for 10–15min. The sections were mounted and photomicrographs were taken at × 20 magnification (Zeiss, Oberkochen, Germany). The number of labeled cells was counted for each rat and brain area using the Image J software (National Institutes of Health—public domain) in both hemispheres of the three non-serial sections closest to those shown in Figure 1. The average of the six values was recorded. The regions examined were chosen on the basis of their association with depression and/or reward (Bechtholt et al, 2008; Hercher et al, 2009; Nestler and Carlezon, 2006; Phillips et al, 2003). Two anatomically close control regions, dorsal striatum (dStr) and ventral posterolaterlal nucleus of the thalamus (VP), were included that have not been heavily implicated in mood or reward.
The Morris Water Maze (MWM) was conducted to determine whether DHK induced hippocampus-associated cognitive impairments. The rats were placed in a large circular pool of opaque water (25°C; 178cm diameter) and allowed to search for a hidden platform for 90s. If the platform was not located within 90s the rat was guided to the platform. The rats remained on the platform for 30s. Two training trials were conducted per day for seven consecutive days. On the eighth day the platform was removed for a probe test and the rats were allowed to search the pool for 60s immediately after being infused with vehicle or 50nmol of DHK. Behavior was recorded and automatically tabulated using an overhead camera and Ethovision software (Noldus, Leesburg, VA).
ICV DHK substantially and dose dependently increased the ICSS thresholds (Figure 2). This conclusion was evidenced by a statistically significant dose × time interaction (F(6, 36)=2.9; p<0.05). The main effects of dose and time were not significant. Follow-up comparisons showed that rats treated with DHK required significantly higher minimum stimulation frequencies to maintain responding (T0) in the first 15min after DHK infusion as compared with the vehicle-treated rats (50.0nmol, p<0.05; 25.0nmol, p<0.01).
Figure 3 shows the effects of DHK on the maximum response rates (Max Rate). Statistical analysis showed a significant main effect of time (F(2, 36)=3.9; p<0.05) and non-significant effects of dose (F(3, 36)=3.0; p=0.059) and the interaction of dose and time (F(6, 36)=1.2; p=0.332). While statistical significance was not reached, a drug-induced suppression of maximal responding is suggested by an apparent flat dose effect of DHK on maximum rate during the first 15min after DHK infusion (Figure 3).
Figure 4 shows the characteristic rightward shift of the rate–frequency function (increased T0) from a representative rat, which indicates a depressant-like (reward decreasing) effect. In addition, a downward shift is shown (decreased Max Rate), which could be the result of decreased hedonic value of the stimulation (Do Carmo et al, 2009) or reduced performance capability (Carlezon and Chartoff, 2007).
In contrast to findings in ICSS, DHK did not induce conditioned place aversion (Figure 5). This conclusion was supported by a lack of significant effects of test, dose, or their interaction. That is, no change in aversion score was observed between tests, suggesting that the rats did not avoid the chamber that had been previously paired with DHK infusion.
As shown in Figure 6, the distance traveled decreased over time during locomotor activity testing with lights off (top panel) or on (bottom panel), and this effect was not affected by DHK infusion. This suggestion was confirmed by statistical analysis showing significant effects of time in both lights off (F(5, 105)=21.8; p=0.001) or lights on (F(5, 87)=19.4; p=0.001) conditions, but no significant effects of dose or dose × time interactions. These null data taken together with ICSS maximum response rate data, suggest that effects observed in ICSS were not the result of sedation.
Figures 7 and and88 show typical c-Fos photomicrographs of representative brain regions, the dorsal dentate gyrus of the hippocampus (dDG) and the infralimbic prefrontal cortex (IL). Table 1 shows the mean number of c-Fos-positive cells for each dose group, the p-values for the one-way ANOVAs, and abbreviations for all of the examined brain regions. The general effects of DHK were replicated across brain areas of interest; DHK dose responsively increased c-Fos expression in many reward and depression related areas, whereas having no effect in the control regions. Significant one-way ANOVAs for the number of c-Fos-positive profiles were observed for the effects of DHK in the AcbC (F(2, 21)=4.2; p<0.05), AcbSh (F(2, 21)=14.8; p<0.001), BL (F(2, 21)=7.8; p<0.005), Ce (F(2, 21)=23.9; p<0.001), IL (F(2, 18)=23.9; p<0.001), DRV (F(2, 22)=12.1; p<0.001); dDG (F(2, 21)=3.9; p<0.05), and LC (F(2, 20)=18.1; p<0.001). Follow-up comparisons and abbreviations are shown in Table 1. No significant effects were observed in the Pir, dCA1, dCA2, dCA3, dStr, MD, and VP.
Groups were well matched before treatment in the MWM. As shown in Figure 9 rats that would later be treated with vehicle or 50nmol of DHK during the probe test showed similar drug-free acquisition patterns in the MWM task. This was shown by a main effect of training day (F(6, 102)=32.7; p<0.001) and by overlapping the distance traveled to the platform that decreased across training days and reached a plateau over days 6 and 7. During the probe test, rats treated with DHK swam faster (t(17)=3.0; p<0.01), searched farther from the former platform location (t(17)=−8.9; p<0.001), and spent less time in the target quadrant (t(17)=3.3; p<0.005) than the vehicle-treated rats. We noted that the DHK-treated animals spent the majority of their time around the perimeter of the pool, whereas the vehicle-treated animals searched the interior. This finding suggests that DHK induces impairments in spatial navigation.
We have shown that blockade of central glial glutamate uptake selectively activates a forebrain circuit involved in the regulation of mood and induces a phenotype with some features of depression. By implication these findings suggest a relationship between a lack of glial cells observed in humans with depression and clinical dysregulation of mood. Here, a lack of astrocytic glial glutamate uptake results in diminished reward value, impaired spatial memory, and activation of brain regions that are associated with motivation. Disruption of glial glutamate uptake is one component of a complex circuit that may mediate anhedonia and cognitive impairment. This finding may provide insight not only into the etiology of depression, but also into the mechanisms underlying the symptoms of other neuropsychiatric illnesses that share these symptoms.
Intracranial DHK increased the ICSS thresholds (T0), the minimum frequency that would sustain responding, suggesting that blocking astrocytic glutamate uptake attenuates brain stimulation reward. This effect is consistent with the induction of an anhedonic-like or dysphoric-like state; two constructs from animal models that represent prominent symptoms of depression (ie, diminished pleasure and depressed or negative mood, respectively). These findings are in agreement with recent work suggesting that glial cells may be involved in the induction or mediation of depressive-like states. For instance, prefrontal cortical glial ablation reportedly decreases sucrose intake, increases response to novelty, and increases immobility in the forced swimming test, effects consistent with a depressant-like effect (Banasr and Duman, 2008). Further, blockade of amygdalar astrocytic glutamate uptake has been reported to decrease social exploration and disrupt circadian rhythms, effects that are also consistent with depression-like symptoms (Lee et al, 2007).
DHK had an effect on the maximal response rate although this was not statistically significant. This effect could be indicative of a performance impairment (Carlezon and Chartoff, 2007), as it has been previously noted that manipulations that interfere with lever pressing, such as muscle relaxation and increasing lever weight, results in lower asymptotic response rates (Miliaressis et al, 1986). It has also been shown that reductions in stimulation intensity or increases in response requirements (eg, changing from an FR1 to an FR10 schedule of reinforcement) can decrease the maximum response rates (Do Carmo et al, 2009), suggesting a relationship between motivation and performance. Examination of frequency–rate curves (eg, Figure 4) shows that both rightward and downward shifts were characteristic of DHK's effect. Together these data indicated that there was a decrease in reward efficacy that could have been accompanied by motor sedation. Consequently, we examined the effects of DHK on locomotor activity, where no signs of sedation were observed. Collectively these data suggest that the threshold-increasing and maximal rate-reducing effects of DHK were not an artifact of performance impairment, but rather the result of reductions in the reward efficacy of the brain stimulation.
Because ICSS provides a relative index of reward (eg, changes in response to rewarding brain stimulation) it is difficult to distinguish between manipulations that induce anhedonia and those that induce dysphoria, as both produce decreases in reward efficacy. In humans, too, although anhedonia and dysphoria may appear together, they represent distinct symptoms that can be observed to varying degrees in different episodes of clinical depression or related illnesses. Place conditioning can be helpful in clarifying the presence of each state because dysphoric effects can be detected as avoidance, without the need for a relative comparison to a reward state. In the present experiments, DHK treatment yielded no significant change in the aversion scores, suggesting that DHK does not provoke discomfort and avoidance of the DHK-paired chamber (ie, no conditioned place aversion). Interpreting these data in combination with the ICSS results make it likely that the effects observed in ICSS were the result of the induction of anhedonia without dysphoria. It should be noted that a lack of an observable effect does not prove that no effect exists, so it is possible that under different conditions DHK would produce dysphoria.
DHK treatment yielded a unique pattern of activation in discrete brain areas that are associated with depression and reward (Hercher et al, 2009; Nestler and Carlezon, 2006; Phillips et al, 2003), without inducing activation in areas that have not been explicitly associated with depression and/or reward. More specifically, c-Fos expression was increased in the AcbC, AcbSh, BL, Ce, IL, DRV, dDG, and LC, but not in the dSTr and VP. In addition to reductions in the volume of some of these mood/reward-related regions (for review see Phillips et al, 2003), specific cellular changes have also been reported in depressed patients (for review see Hercher et al, 2009). A reduction in glial cells or associated markers has been noted in the prefrontal cortex (Cotter et al, 2001, 2002; Öngür et al, 1998; Rajkowska et al, 1999), hippocampus (Müller et al, 2001), and amygdala (Bowley et al, 2002; Hamidi et al, 2004). By contrast, reductions in neurons or their markers have been noted in the the prefrontal cortex (Rajkowska et al, 1999, 2005, 2007), dorsal raphe nucleus (Baumann et al, 2002), and locus coeruleus (Arango et al, 1996). To be clear, the raphe nucleus and the locus coeruleus have not yet been examined for glial abnormalities. These regions are part of a large interconnected circuit with projections from the prefrontal cortex to the ventromedial striatum (Öngür and Price, 2000) and raphe nucleus, and projections from the locus coeruleus to the raphe nucleus (Marcinkiewicz et al, 1989), as well as reciprocal connections between the medial prefrontal cortex, amygdala, and the enorhinal cortex (Öngür and Price, 2000). Because these regions are so highly connected, it is not possible at this time to distinguish between c-Fos expression resulting from the direct effects of blocking glial glutamate uptake in a given locus and expression that is an indirect consequence of activation through projections. Nonetheless, these data begin to characterize how glial deficits can produce depressive-like effects and serve to highlight important candidate regions for further study.
We observed robust activation of the dentate gyrus of the hippocampus after DHK treatment that was accompanied by deficits in hippocampus-dependent spatial navigation. Although little is known about effects in mammals, astrocyte trafficking of glutamate has been heavily implicated in learning and memory consolidation in chicks (for review see Gibbs et al, 2008) and the hippocampus has been extensively studied with respect to depression. In patients with unremitted depression, hippocampal volumes are decreased (Sheline et al, 2003) and numerous cognitive deficits have been documented (Clark et al, 2009). Impaired spatial navigation, which requires the hippocampus, is among these cognitive deficits (Gould et al, 2007). Likewise, animal models of depression show major alterations in hippocampal plasticity and structure (Duman, 2004; Kim et al, 2006) that can be accompanied by impaired spatial navigation (Song et al, 2006; Sun and Alkon, 2004). The present results are in agreement with these many findings and extend them to suggest that similar mechanisms involving astrocyte dysfunction may underlie both cognitive and reward-related symptoms in depression.
One might suspect that DHK-induced cognitive impairment could underlie the decreased responding in the ICSS paradigm and a lack of conditioned place aversion in the place conditioning paradigm. Some evidence suggests otherwise. There is a large published literature showing that many drugs that are well known to impair spatial learning and memory (eg, MK-801; Whishaw and Auer, 1989) actually facilitate, rather than impair, ICSS responding (Corbett, 1989). Furthermore, the unique timing of the effects in this paradigm diminishes the likelihood that learning or memory impairment decreased the responding for rewarding brain stimulation. The frequencies were presented in a descending order for 50s each. Here, rats responded normally for the highest frequencies, which were presented first, and anhedonia was shown by a lack of responding at lower frequencies. As such, the change in responding for a given frequency occurred during the 5-s timeout and the 0.5-s non-contingent stimulus train that came between trials. This normal initial responding coupled with the rapid transition from responding to not responding suggests that the rats were able to recall the task. For place conditioning, there is evidence in the literature that rats seek novelty (eg, reference Hughes, 1968). If DHK disrupted memory, we would expect the DHK-paired chamber to be novel relative to the vehicle-paired chamber. By extension, we would expect the rats to prefer the DHK-paired environment, for its novelty, relative to the vehicle-paired chamber. The observation that the rats spent equal amounts of time in the DHK- and saline-paired chambers suggests that each was equally familiar, and supports the hypothesis that DHK neither produced dysphoria nor disrupted place conditioning.
Here we suggest an important role for astrocytes in the etiology of anhedonia and cognitive dysfunction in depression. However, these symptoms are not unique to depression as they are shared by a number of neuropsychiatric disorders, including, but not limited to; bipolar disorder, schizophrenia, and Parkinson's disease (Andreasen and Olsen, 1982; Burdick et al, 2007; Cassidy et al, 2000; Gorwood, 2008; Ibarretxe-Bilbao et al, 2009; Isella et al, 2003; Kraus and Keefe, 2007). Of particular interest is bipolar disorder, for which an unspecified reduction in glial cell density and number has also been reported (Öngür et al, 1998; Rajkowska, 2002; Rajkowska et al, 2001). Abnormalities in specific glial cell subtypes have been strongly implicated in schizophrenia and Parkinson's disease, as well, although lack of astrocytes has not been suggested in these disorders (Bernstein et al, 2009; Mena and Garcia de Yebenes, 2008). Nevertheless, there is a suggested relationship between anhedonia, cognitive dysfunction, and glial cells in a number of neuropsychiatric disorders. Thus, our findings may have implications beyond depression. Indeed, a current active discussion in psychiatry is underway as to whether psychiatric disorders are best conceived as separate illnesses with separate pathophysiologies or as illnesses along several dimensions of disorder, such as mood or cognitive disorder, with overlapping underlying pathologies in particular neurotransmitter (eg, glutamate) or cellular (eg, glial) systems shared to varying degrees among the illnesses.
DHK treatment provided a model to mimic some aspects of what might occur clinically as a consequence of a paucity or dysfunction of glial cells. This treatment appeared to induce anhedonia, absent dysphoria, and cognitive impairment suggesting that a lack of astrocytic glutamate uptake could have a causal role in producing specific symptoms of depression. Furthermore, DHK induced the activation of a limited number of brain areas that are thought to be key in the regulation of mood. These findings broaden our understanding of the underlying pathophysiology of depression, highlight possible novel sites of action for the development of new treatments, and may be important for other neuropsychiatric disorders that, like depression, include anhedonia and cognitive impairment as symptoms.
This work was supported by grants from and the National Alliance for Research on Schizophrenia and Depression (NARSAD—AJBG), the Jerome Lyle Rappaport Charitable Foundation (AJBG), the Shervert Frazier Research Institute (BMC), the Englehard Foundation (BMC), and the National Institutes of Mental Health (MH087695, AJBG; MH063266, WAC). We thank Elena Chartoff for providing the c-Fos antibody.
The authors have no conflicts of interest relating to this report and Dr Bechtholt-Gompf, Hali Walther, and Martha Adams have no other potential conflicts to report. Dr Carlezon has a US patent covering the use of kappa antagonists in the treatment of depression (Assignee: McLean Hospital) and is a member of a collaborative group, including Dr Cohen, that has submitted a patent application covering the synthesis and use of salvinorin derivatives (Assignees: McLean Hospital and Temple University). In the last 3 years Dr Carlezon has received compensation for professional services from The American College of Neuropsychopharmacology, Huya Bioscience International, Infinity Pharmaceuticals, Lantheus Medical Imaging, The Society for Neuroscience, and Transcept Pharmaceuticals. Dr Öngür received Riluzole for a study from Sanofi-Aventis during the past 3 years. Dr Cohen has three additional pending patents on pyrimidines to treat bipolar disorders, kappa agonists in bipolar mania, and mitochondrial replacement therapy, and a book on bipolar disorder that will be published by Jossey-Bass/Wiley within the next year.